Author

Heinz Wiendl

University of M

Biography

Heinz Wiendl is professor of Neurology and chair of the Department of Neurology at the University Hospital of Muenster. In addition he is dean for research and young academics of the medical faculty Muenster, representative of the academia in the University clinic’s board of directors and head of a research group working in the field of neuroimmunology.
Title
Cited by
Year
Clinical, serological and genetic predictors of response to immunotherapy in anti-IgLON5 disease
T Grüter, FE Möllers, A Tietz, J Dargvainiene, N Melzer, A Heidbreder, ...Brain 146 (2), 600-611, 2023202
24
2023
Serum glial fibrillary acidic protein compared with neurofilament light chain as a biomarker for disease progression in multiple sclerosis
S Meier, EAJ Willemse, S Schaedelin, J Oechtering, J Lorscheider, ...JAMA neurology 0 (3), 27-297, 2023202
8
2023
A genome-wide association study in autoimmune neurological syndromes with anti-GAD65 autoantibodies
A genome-wide association study in autoimmune neurological syndromes with anti-GAD6 autoantibodiesC Strippel, M Herrera-Rivero, M Wendorff, AK Tietz, F Degenhardt, ...Brain 146 (3), 977-990, 2023202
5
2023
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study
V Bril, A Drużdż, J Grosskreutz, AA Habib, R Mantegazza, S Sacconi, ...The Lancet Neurology 22 (5), 383-39, 2023202
4
2023
Humoral signatures of MOG-antibody-associated disease track with age and disease activity
M Spatola, O Chuquisana, W Jung, JA Lopez, EM Wendel, ...Cell Reports Medicine (2), 2023202
4
2023
Distinct movement disorders in contactin-associated-protein-like-2 antibody-associated autoimmune encephalitis
F Gövert, L Abrante, J Becktepe, B Balint, C Ganos, U Hofstadt-van Oy, ...Brain 146 (2), 657-667, 20220
3
2023
Five-Year Safety of Ofatumumab in People Living With Relapsing Multiple Sclerosis
JA Cohen, SL Hauser, AH Cross, K Winthrop, H Wiendl, J Nicholas, ...Presented at the CMSC Annual Meeting 202, 20220
3
2023
A novel NMDA receptor test model based on hiPSC-derived neural cells
P Disse, I Aymanns, N Ritter, S Peischard, L Korn, H Wiendl, M Pawlowski, ...Biological Chemistry 404 (4), 67-77, 030
2
2023
Bruton tyrosine kinase inhibitors for multiple sclerosis
J Krämer, A Bar-Or, TJ Turner, H WiendlNature Reviews Neurology, 1-16, 030
2
2023
MAPT genotype-dependent mitochondrial aberration and ROS production trigger dysfunction and death in cortical neurons of patients with hereditary FTLD
L Korn, AM Speicher, CB Schroeter, L Gola, T Kaehne, A Engler, P Disse, ...Redox Biology 59, 10597, 030
2
2023
Molecular biomarkers and cognitive impairment in multiple sclerosis: state of the field, limitations, and future direction–A systematic review and meta-analysis
TD Rademacher, SG Meuth, H Wiendl, A Johnen, NC LandmeyerNeuroscience & Biobehavioral Reviews, 105035, 030
2
2023
Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for …
LZ Ryerson, JF Foley, G Defer, JA Cohen, DL Arnold, H Butzkueven, ...Multiple Sclerosis and Related Disorders 72, 0456, 2023202
1
2023
Association of age with 1-year outcome in patients with acute ischaemic stroke treated with thrombectomy: real-world analysis in 18 506 patients
Association of age with -year outcome in patients with acute ischaemic stroke treated with thrombectomy: real-world analysis in 8 506 patientsC Beuker, J Köppe, J Feld, CL Meyer, P Dröge, T Ruhnke, C Günster, ...Journal of Neurology, Neurosurgery & Psychiatry, 2023202
1
2023
Efficacy and safety of proposed biosimilar natalizumab (PB006) in patients with relapsing-remitting multiple sclerosis: the Antelope phase 3 randomized clinical trial
B Hemmer, H Wiendl, K Roth, H Wessels, J Höfler, C Hornuss, B Liedert, ...JAMA neurology 80 (3), 298-307, 2023202
1
2023
Early Onset of Action and Sustained Efficacy of MRI Outcomes During Cladribine Tablets Treatment in Highly Active Relapsing Multiple Sclerosis: Results of the 2-year MAGNIFY-MS …
N De Stefano, A Achiron, F Barkhof, A Chan, T Derfuss, S Hodgkinson, ...Neurology 00 (7 Supplement 2), 2023202
1
2023
Five-year safety of ofatumumab in people living with relapsing multiple sclerosis (P8-3.004)
J Cohen, S Hauser, A Cross, K Winthrop, H Wiendl, J Nicholas, S Meuth, ...Neurology 00 (7 Supplement 2), 2023202
1
2023
Early spinal cord pseudoatrophy in interferon‐beta‐treated multiple sclerosis
B Matusche, L Litvin, R Schneider, B Bellenberg, M Mühlau, V Pongratz, ...European Journal of Neurology 30 (2), 453-462, 2023202
1
2023

Referred From: https://scholar.google.com/citations?user=oZ9aiqYAAAAJ&hl=en

Cited by
Citations 33547
h-index 95
i10-index 476
Recommended Journals
Open Access Journals